Comparative Pharmacology
Head-to-head clinical analysis: AK PENTOLATE versus AKPENTOLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AK PENTOLATE versus AKPENTOLATE.
AK-PENTOLATE vs AKPENTOLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimuscarinic and anticholinergic agent that blocks muscarinic acetylcholine receptors, producing mydriasis and cycloplegia.
Ocular hypotensive agent; reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes of the eye.
1 to 2 drops of 1% solution in the eye(s) every 5 to 10 minutes for 1 to 2 doses prior to examination.
1-2 mg intravenously every 4-6 hours as needed for nausea and vomiting; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours in adults; prolonged in neonates (up to 12 hours) due to immature hepatic and renal function.
Terminal elimination half-life is 3.5 hours (range 2.5-5 hours) in healthy adults; clinically, steady-state is reached within 12-15 hours with regular dosing.
Renal 85% as unchanged drug; fecal 10% as metabolites; biliary 5%.
Renal elimination of unchanged drug accounts for 75-85% of clearance; biliary/fecal elimination accounts for 15-25%, with less than 5% as metabolites.
Category C
Category C
Anticholinergic Mydriatic
Anticholinergic Mydriatic